Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Arcus Biosciences, Inc. Director's Dealing 2025

Jan 27, 2025

31966_dirs_2025-01-27_4f16fb8b-70d6-468e-9678-079d22c90ab5.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Arcus Biosciences, Inc. (RCUS)
CIK: 0001724521
Period of Report: 2025-01-23

Reporting Person: Jaen Juan C. (President)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2025-01-23 Common Stock A 50000 Acquired 367220 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2025-01-23 Stock Option (right to buy) $13.33 A 200000 Acquired 2035-01-22 Common Stock (200000) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 1188233 Indirect

Footnotes

F1: Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2025, subject to the Reporting Person's continued service to the Company.

F2: The option becomes exercisable in 48 equal monthly installments after January 1, 2025, subject to the Reporting Person's continued service to the Company.